These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 24307899)

  • 1. Efficacy of goshajinkigan for oxaliplatin-induced peripheral neuropathy in colorectal cancer patients.
    Yoshida N; Hosokawa T; Ishikawa T; Yagi N; Kokura S; Naito Y; Nakanishi M; Kokuba Y; Otsuji E; Kuroboshi H; Taniwaki M; Taguchi T; Hosoi H; Nakamura T; Miki T
    J Oncol; 2013; 2013():139740. PubMed ID: 24307899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen.
    Nishioka M; Shimada M; Kurita N; Iwata T; Morimoto S; Yoshikawa K; Higashijima J; Miyatani T; Kono T
    Int J Clin Oncol; 2011 Aug; 16(4):322-7. PubMed ID: 21258836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis.
    Kuriyama A; Endo K
    Support Care Cancer; 2018 Apr; 26(4):1051-1059. PubMed ID: 29280005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of goshajinkigan for peripheral neurotoxicity of oxaliplatin in patients with advanced or recurrent colorectal cancer.
    Kono T; Mamiya N; Chisato N; Ebisawa Y; Yamazaki H; Watari J; Yamamoto Y; Suzuki S; Asama T; Kamiya K
    Evid Based Complement Alternat Med; 2011; 2011():418481. PubMed ID: 19952054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double‑blind, placebo‑controlled trial of goshajinkigan to prevent oxaliplatin‑induced neuropathy.
    Kono T; Hata T; Morita S; Munemoto Y; Matsui T; Kojima H; Takemoto H; Fukunaga M; Nagata N; Shimada M; Sakamoto J; Mishima H
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1283-90. PubMed ID: 24121454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Goshajinkigan for reducing chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis.
    Hoshino N; Ganeko R; Hida K; Sakai Y
    Int J Clin Oncol; 2018 Jun; 23(3):434-442. PubMed ID: 29270698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study.
    Oki E; Emi Y; Kojima H; Higashijima J; Kato T; Miyake Y; Kon M; Ogata Y; Takahashi K; Ishida H; Saeki H; Sakaguchi Y; Yamanaka T; Kono T; Tomita N; Baba H; Shirabe K; Kakeji Y; Maehara Y
    Int J Clin Oncol; 2015 Aug; 20(4):767-75. PubMed ID: 25627820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Objective evaluation of the alleviating effects of Goshajinkigan on peripheral neuropathy induced by paclitaxel/carboplatin therapy: A multicenter collaborative study.
    Kaku H; Kumagai S; Onoue H; Takada A; Shoji T; Miura F; Yoshizaki A; Sato S; Kigawa J; Arai T; Tsunoda S; Tominaga E; Aoki D; Sugiyama T
    Exp Ther Med; 2012 Jan; 3(1):60-65. PubMed ID: 22969845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Goshajinkigan reduces oxaliplatin-induced peripheral neuropathy without affecting anti-tumour efficacy in rodents.
    Ushio S; Egashira N; Sada H; Kawashiri T; Shirahama M; Masuguchi K; Oishi R
    Eur J Cancer; 2012 Jun; 48(9):1407-13. PubMed ID: 21907570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An effective therapeutic approach for oxaliplatin-induced peripheral neuropathy using a combination therapy with goshajinkigan and bushi.
    Mizuno K; Shibata K; Komatsu R; Omiya Y; Kase Y; Koizumi S
    Cancer Biol Ther; 2016 Nov; 17(11):1206-1212. PubMed ID: 27416484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Goshajinkigan, a traditional Japanese medicine, prevents oxaliplatin-induced acute peripheral neuropathy by suppressing functional alteration of TRP channels in rat.
    Mizuno K; Kono T; Suzuki Y; Miyagi C; Omiya Y; Miyano K; Kase Y; Uezono Y
    J Pharmacol Sci; 2014; 125(1):91-8. PubMed ID: 24784702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of controlled-release oxycodone for oxaliplatin-induced peripheral neuropathy and the extension of FOLFOX therapy in advanced colorectal cancer patients.
    Nagashima M; Ooshiro M; Moriyama A; Sugishita Y; Kadoya K; Sato A; Kitahara T; Takagi R; Urita T; Yoshida Y; Tanaka H; Oshiro T; Okazumi S; Katoh R
    Support Care Cancer; 2014 Jun; 22(6):1579-84. PubMed ID: 24452412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Herbal Medicine Goshajinkigan Prevents Paclitaxel-Induced Mechanical Allodynia without Impairing Antitumor Activity of Paclitaxel.
    Bahar MA; Andoh T; Ogura K; Hayakawa Y; Saiki I; Kuraishi Y
    Evid Based Complement Alternat Med; 2013; 2013():849754. PubMed ID: 24198846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study.
    El-Fatatry BM; Ibrahim OM; Hussien FZ; Mostafa TM
    Int J Colorectal Dis; 2018 Dec; 33(12):1675-1683. PubMed ID: 29931409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Vitamin E on Oxaliplatin-induced Peripheral Neuropathy Prevention: A Randomized Controlled Trial.
    Salehi Z; Roayaei M
    Int J Prev Med; 2015; 6():104. PubMed ID: 26682028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperacute peripheral neuropathy is a predictor of oxaliplatin-induced persistent peripheral neuropathy.
    Tanishima H; Tominaga T; Kimura M; Maeda T; Shirai Y; Horiuchi T
    Support Care Cancer; 2017 May; 25(5):1383-1389. PubMed ID: 27921224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. L-Carnosine protects against Oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: A perspective on targeting Nrf-2 and NF-κB pathways.
    Yehia R; Saleh S; El Abhar H; Saad AS; Schaalan M
    Toxicol Appl Pharmacol; 2019 Feb; 365():41-50. PubMed ID: 30592963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: RILUZOX-01: protocol of a randomised, parallel, controlled, double-blind and multicentre study by the UNICANCER-AFSOS Supportive Care intergroup.
    Kerckhove N; Busserolles J; Stanbury T; Pereira B; Plence V; Bonnetain F; Krakowski I; Eschalier A; Pezet D; Balayssac D
    BMJ Open; 2019 Jun; 9(6):e027770. PubMed ID: 31182448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective effect of the oral administration of cystine and theanine on oxaliplatin-induced peripheral neuropathy: a pilot randomized trial.
    Kobayashi M; Sato R; Komura T; Ichikawa H; Hirashima T; Otake S; Akazawa N; Yazawa T; Abe T; Okada T; Kakita T; Oikawa M; Tsuchiya T
    Int J Clin Oncol; 2020 Oct; 25(10):1814-1821. PubMed ID: 32594273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of oxaliplatin-induced peripheral neuropathy by a polyamine-reduced diet-NEUROXAPOL: protocol of a prospective, randomised, controlled, single-blind and monocentric trial.
    Balayssac D; Ferrier J; Pereira B; Gillet B; Pétorin C; Vein J; Libert F; Eschalier A; Pezet D
    BMJ Open; 2015 Apr; 5(4):e007479. PubMed ID: 25833669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.